Acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1

Name
Acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1
ICD-O-3 Morphology
9896/3
Effective 2001 and later
Reportable
for cases diagnosed 2001 and later
Primary Site(s)
C421

Help me code for dx year :

Grade
Code grade specified by pathologist. If no grade specified, code 9
Module Rule
M3 Module 5: PH10
Alternate Names
Acute myeloid leukemia with recurrent genetic abnormalities
Acute myeloid leukemia, AML1(CBF-Alpha)/ETO
Acute myeloid leukemia, FLT3-TKD
Acute myeloid leukemia, t(8;21)(q22;q22)
AML1/ETO
FAB M2, AML1(CBF-Alpha)/ETO
FAB M2, t(8;21)(q22;q22)
Definition
The t(8;21)(q22;q22) translocation juxtaposes the AML1 gene on chromosome 21 to the ETO for t(I;21) gene on chromosome 8, which results in the production of the AML-ETO fusion protein.
AML with t(8;21)(q22;q22) is an acute myeloid leukemia generally showing maturation in the neutrophil lineage. This translocation is one of the most common (5-12% of AML cases).
Myeloid sarcomas (chloromas) may be present and may be associated with a bone marrow blast percentage of less than 20%.
If translocation present, categorize as AML even if initial blast count is < 20%.
Abstractor Notes
Tumor manifestations such as myeloid sarcomas may be present at diagnosis; in these cases an initial BM aspiration may show a misleading low number of blast cells but should be diagnosed as AML despite a blast percentage in BM of less than 20. Smaller blasts may be found in the PB.
Definitive Diagnostic Methods
Bone marrow biopsy
Genetic testing
Immunophenotyping
Genetics Data
del(9q)
RUNX1-RUNX1T1
t(8;21)(q22;q22)
Immunophenotyping
CD13
CD33 (weak expression)
CD34
CD56 (expressed in a fraction of cases)
Treatments
Chemotherapy
Transformations to
None
Corresponding ICD-9 Codes
205.0 Acute myeloid leukemia
Corresponding ICD-10 Codes
C92.0 Acute myeloid leukemia
Corresponding ICD-10-CM Codes (effective October 1, 2015 U.S. only)
C92.0 Acute myeloblastic leukemia
Signs and Symptoms
None
Diagnostic Exams
None
Recurrence and Metastases
None
Epidemiology and Mortality
None